Kim Askew to Troponin
This is a "connection" page, showing publications Kim Askew has written about Troponin.
Connection Strength
0.125
-
Riley RF, Miller CD, Russell GB, Harper EN, Hiestand BC, Hoekstra JW, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Mahler SA. Cost analysis of the History, ECG, Age, Risk factors, and initial Troponin (HEART) Pathway randomized control trial. Am J Emerg Med. 2017 Jan; 35(1):77-81.
Score: 0.033
-
Stopyra JP, Miller CD, Hiestand BC, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Riley RF, Russell GB, Burke GL, Herrington D, Hoekstra JW, Mahler SA. Chest Pain Risk Stratification: A Comparison of the 2-Hour Accelerated Diagnostic Protocol (ADAPT) and the HEART Pathway. Crit Pathw Cardiol. 2016 06; 15(2):46-9.
Score: 0.032
-
Stopyra JP, Miller CD, Hiestand BC, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Riley RF, Russell GB, Hoekstra JW, Mahler SA. Performance of the EDACS-accelerated Diagnostic Pathway in a Cohort of US Patients with Acute Chest Pain. Crit Pathw Cardiol. 2015 Dec; 14(4):134-8.
Score: 0.031
-
Mahler SA, Riley RF, Hiestand BC, Russell GB, Hoekstra JW, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Elliott SB, Herrington DM, Burke GL, Miller CD. The HEART Pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge. Circ Cardiovasc Qual Outcomes. 2015 Mar; 8(2):195-203.
Score: 0.029